/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
Edwards Lifesciences Corporation (EW), a global leader in patient-focused medical innovations, was founded in 1958 and is headquartered in Irvine, California. With a market cap of $42.2 billion, Edwards Lifesciences is a key player in the healthcare industry, specializing in cutting-edge technologies for structural heart disease and critical care monitoring.
Companies with a market value of $10 billion or more are classified as “large-cap stocks,” Edwards Lifesciences firmly belongs in this category. With a strong track record of financial performance and a commitment to advancing medical technology, Edwards excels in specialized healthcare sectors, including structural heart innovations and critical care solutions. Its innovative products and patient-focused approach drive significant impact across global healthcare markets.
Edwards Lifesciences is currently trading 25.6% below its 52-week high of $96.12, reached on Mar. 28. Shares of Edwards Lifesciences gained 7.1% over the three months, underperforming the broader S&P 500 Index ($SPX) 12.6% gains during the same time frame.
Over the longer term, EW has posted a YTD loss of 6.2%, falling short of SPX's 27.7% return. Similarly, over the past 52 weeks, EW reported a 2.9% gain, underperforming SPX's impressive 33.9% growth during the same period.
To confirm the recent bearish trend, EW has consistently traded below its 200-day moving average since late July. However, it has stayed above its 50-day moving average since mid-November.
On Oct. 24, Edwards Lifesciences posted its Q3 results, with shares closing slightly lower despite solid performance. The company reported an adjusted EPS of $0.67, aligning with consensus estimates and reflecting a strong 21.8% year-over-year growth. Revenue came in at $1.35 billion, marking an 8.9% increase compared to the prior year. Edwards reaffirmed its full-year sales growth outlook of 8% to 10% and maintained guidance across its three key product segments. For Q4, the company anticipates revenue in the range of $1.33 billion to $1.39 billion, with projected EPS between $0.53 and $0.57.
Edwards Lifesciences has lagged behind its competitor, Medtronic plc (MDT). MDT stock has edged up 2% on a YTD basis and returned 6.3% over the past 52 weeks.
Despite EW underperforming the broader sector, analysts maintain a moderately bullish outlook on the stock. Of the 27 analysts covering it, the consensus rating is “Moderate Buy,” with a mean price target of $76.46, indicating a potential upside of 6.9% from its current level.
